JP2017511329A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511329A5
JP2017511329A5 JP2016560389A JP2016560389A JP2017511329A5 JP 2017511329 A5 JP2017511329 A5 JP 2017511329A5 JP 2016560389 A JP2016560389 A JP 2016560389A JP 2016560389 A JP2016560389 A JP 2016560389A JP 2017511329 A5 JP2017511329 A5 JP 2017511329A5
Authority
JP
Japan
Prior art keywords
oxy
amine
dimethylpentan
methyl
difluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511329A (ja
JP6411541B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023805 external-priority patent/WO2015153720A1/en
Publication of JP2017511329A publication Critical patent/JP2017511329A/ja
Publication of JP2017511329A5 publication Critical patent/JP2017511329A5/ja
Application granted granted Critical
Publication of JP6411541B2 publication Critical patent/JP6411541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560389A 2014-04-02 2015-04-01 ビアリールキナーゼ阻害剤 Active JP6411541B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461973942P 2014-04-02 2014-04-02
US61/973,942 2014-04-02
US201462061591P 2014-10-08 2014-10-08
US62/061,591 2014-10-08
PCT/US2015/023805 WO2015153720A1 (en) 2014-04-02 2015-04-01 Biaryl kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2017511329A JP2017511329A (ja) 2017-04-20
JP2017511329A5 true JP2017511329A5 (enExample) 2018-03-15
JP6411541B2 JP6411541B2 (ja) 2018-10-24

Family

ID=52988448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560389A Active JP6411541B2 (ja) 2014-04-02 2015-04-01 ビアリールキナーゼ阻害剤

Country Status (27)

Country Link
US (7) US9902722B2 (enExample)
EP (1) EP3126351B1 (enExample)
JP (1) JP6411541B2 (enExample)
KR (1) KR102379518B1 (enExample)
CN (1) CN106458994B (enExample)
AU (1) AU2015240869B2 (enExample)
BR (1) BR112016022298B1 (enExample)
CA (1) CA2944466C (enExample)
CL (1) CL2016002502A1 (enExample)
CY (1) CY1120988T1 (enExample)
DK (1) DK3126351T3 (enExample)
EA (1) EA028942B1 (enExample)
ES (1) ES2700549T3 (enExample)
HR (1) HRP20181899T1 (enExample)
HU (1) HUE041457T2 (enExample)
IL (1) IL248086B (enExample)
LT (1) LT3126351T (enExample)
MX (1) MX2016012829A (enExample)
PE (1) PE20170004A1 (enExample)
PL (1) PL3126351T3 (enExample)
PT (1) PT3126351T (enExample)
RS (1) RS58062B1 (enExample)
SG (1) SG11201608195QA (enExample)
SI (1) SI3126351T1 (enExample)
SM (1) SMT201800665T1 (enExample)
WO (1) WO2015153720A1 (enExample)
ZA (1) ZA201606767B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517993B (zh) 2013-07-08 2018-07-13 百时美施贵宝公司 芳基酰胺激酶抑制剂
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
DK3105218T3 (da) 2014-02-13 2019-11-04 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
PE20170004A1 (es) * 2014-04-02 2017-03-04 Bristol Myers Squibb Co Inhibidores de biaril cinasa
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
WO2016164295A2 (en) * 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
UA126277C2 (uk) 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
KR102704295B1 (ko) * 2015-10-01 2024-09-05 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
WO2017059080A1 (en) * 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
US11161843B2 (en) 2017-01-24 2021-11-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
TW202120495A (zh) * 2019-08-02 2021-06-01 美商愛彼特生物製藥股份有限公司 經取代環丙基—2,2'—聯嘧啶基化合物、其類似物及其使用方法
US11666575B2 (en) 2020-04-21 2023-06-06 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections
CN115484951A (zh) * 2020-04-21 2022-12-16 莱西肯医药有限公司 用于治疗病毒感染的aak1抑制剂
EP4159719A4 (en) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
TW202210462A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 (s)-2-胺基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其鹽的製備方法
EP4371980A4 (en) * 2021-07-15 2024-12-11 Xizang Haisco Pharmaceutical Co., Ltd. AAK1 INHIBITOR AND USE THEREOF
CN115872927A (zh) * 2021-09-30 2023-03-31 武汉人福创新药物研发中心有限公司 Aak1抑制剂及其用途
CN119095826A (zh) * 2022-03-01 2024-12-06 莱西肯医药有限公司 用于合成aak1抑制剂的方法和化合物
AU2023229156A1 (en) * 2022-03-01 2024-08-15 Lexicon Pharmaceuticals, Inc. Solid forms of (s)-l-((2',6-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof
EP4496788A1 (en) 2022-03-23 2025-01-29 Teva Pharmaceuticals International GmbH Solid state forms of lx9211 and salts thereof
TW202423433A (zh) * 2022-11-10 2024-06-16 大陸商西藏海思科製藥有限公司 含aak1抑制劑的藥物组合物
CN120344529A (zh) * 2022-12-13 2025-07-18 上海海雁医药科技有限公司 杂环取代的五并六元杂芳基衍生物、其药物组合物及应用与制备方法
CN120641406A (zh) * 2023-01-16 2025-09-12 上海海雁医药科技有限公司 杂环取代的含氮杂环衍生物、其药物组合物及应用与制备方法
AU2024253688A1 (en) * 2023-04-07 2025-10-23 Alicorn Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound as aak1 inhibitor
CN118772152B (zh) * 2023-04-07 2026-01-02 艾立康药业股份有限公司 作为aak1抑制剂的氮杂环类化合物
WO2025092928A1 (zh) * 2023-11-02 2025-05-08 西藏海思科制药有限公司 一种可抑制连接蛋白相关激酶1的化合物、制备及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003286895A1 (en) 2002-11-05 2004-06-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
WO2005085227A1 (en) * 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
CN101460491A (zh) * 2006-04-12 2009-06-17 惠氏公司 苯胺基嘧啶苯基和苯并噻吩类似物
NZ578744A (en) * 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
US8703953B2 (en) * 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
WO2013134336A2 (en) * 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP2958924B1 (en) 2013-02-22 2016-12-28 Bristol-Myers Squibb Company 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
CN105517993B (zh) 2013-07-08 2018-07-13 百时美施贵宝公司 芳基酰胺激酶抑制剂
CN105683196B (zh) 2013-09-11 2018-12-21 百时美施贵宝公司 基于芳基醚的激酶抑制剂
JP6276865B2 (ja) 2014-01-29 2018-02-07 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アリールラクタムキナーゼ阻害剤
WO2015116492A1 (en) 2014-01-31 2015-08-06 Bristol-Myers Squibb Company Quinoline-based kinase inhibitors
PE20170004A1 (es) 2014-04-02 2017-03-04 Bristol Myers Squibb Co Inhibidores de biaril cinasa
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
WO2016164295A2 (en) 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
KR102704295B1 (ko) 2015-10-01 2024-09-05 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
WO2017059080A1 (en) 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
EP3818007B1 (en) 2018-07-06 2025-04-16 Liqui-Box Corporation Dispensing probe for dispensing flowable material

Similar Documents

Publication Publication Date Title
JP2017511329A5 (enExample)
JP2018537408A5 (enExample)
NZ609955A (en) Sgc stimulators
ES2675760T3 (es) Compuestos terapéuticamente activos y métodos de uso de los mismos
JP5367707B2 (ja) Dhodh阻害剤としてのアザビフェニルアミノ安息香酸誘導体
JP2016523977A5 (enExample)
JP2016525076A5 (enExample)
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
JP2016525075A5 (enExample)
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
US10376510B2 (en) 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
JP2020502111A5 (enExample)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP2015172062A5 (enExample)
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2017530962A5 (enExample)
JP2011503230A5 (enExample)
RU2014124953A (ru) Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
JP2016522232A5 (enExample)
JP2012525395A5 (enExample)
RU2019121871A (ru) Новые производные фенилпропионовой кислоты и их применение
CA2624602A1 (en) Process for preparing 6-substituted-7-azaindoles
JP2017523214A5 (enExample)
JP2013500997A5 (enExample)
RU2016102313A (ru) Биарильные производные в качестве агонистов gpr120